Trial Profile
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2012
Price :
$35
*
At a glance
- Drugs Pilaralisib (Primary) ; Voxtalisib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Pharmacodynamics
- 26 Jul 2012 Actual end date (1 Jun 2012)added as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 May 2012 Planned end date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.